AL001, an anti-sortilin antibody, has currently reached a phase III study for treatment of frontotemporal dementia (NCT04374136), and TH1902, a drug consisting of docetaxel conjugated to a sortilin-targeting peptide, is currently being tested in a phase I study for treatment of several solid cancers (NCT04706962). The gene discussed is SORT1; the disease is frontotemporal dementia.